Monro, S. et al. Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities and highlights from the development of TLD1433. Chem. Rev. 119, 797–828 (2018).
Farrer, N. J., Salassa, L. & Sadler, P. J. Photoactivated chÿemotherapy (PACT): the potential of excited-state d-block metals in medicine. Dalton Trans. 2009, 10690–10701 (2009).
Li, X., Lovell, J. F., Yoon, J. & Chen, X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat. Rev. Clin. Oncol. 17, 657–674 (2020).
Agostinis, P. et al. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 61, 250–281 (2011).
Celli, J. P. et al. Imaging and photodynamic therapy: mechanisms, monitoring and optimization. Chem. Rev. 110, 2795–2838 (2010).
McFarland, S. A., Mandel, A., Dumoulin-White, R. & Gasser, G. Metal-based photosensitizers for photodynamic therapy: the future of multimodal oncology? Curr. Opin. Chem. Biol. 56, 23–27 (2020).
Du, J. et al. Enhanced photodynamic therapy for overcoming tumor hypoxia: from microenvironment regulation to photosensitizer innovation. Coord. Chem. Rev. 427, 213604 (2021).
Baptista, M. S. et al. Type I and type II photosensitized oxidation reactions: guidelines and mechanistic pathways. Photochem. Photobiol. 93, 912–919 (2017).
Allison, R. R. & Sibata, C. H. Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagnosis Photodyn. Ther. 7, 61–75 (2010).
Heinemann, F., Karges, J. & Gasser, G. Critical overview of the use of Ru(II) polypyridyl complexes as photosensitizers in one-photon and two-photon photodynamic therapy. Acc. Chem. Res. 50, 2727–2736 (2017).
Dewaele, M. et al. Autophagy pathways activated in response to PDT contribute to cell resistance against ROS damage. J. Cell. Mol. Med. 15, 1402–1414 (2011).
Persi, E. et al. Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat. Commun. 9, 2997 (2018).
Corbet, C. & Feron, O. Tumour acidosis: from the passenger to the driver’s seat. Nat. Rev. Cancer 17, 577–593 (2017).
Pawlicki, M., Collins, H. A., Denning, R. G. & Anderson, H. L. Two‐photon absorption and the design of two‐photon dyes. Angew. Chem. Int. Ed. 48, 3244–3266 (2009).
Imberti, C., Zhang, P., Huang, H. & Sadler, P. J. New designs for phototherapeutic transition metal complexes. Angew. Chem. Int. Ed. 59, 61–73 (2020).
Wexselblatt, E., Yavin, E. & Gibson, D. Platinum(IV) prodrugs with haloacetato ligands in the axial positions can undergo hydrolysis under biologically relevant conditions. Angew. Chem. Int. Ed. 52, 6059–6062 (2013).
Deng, Z. et al. A photocaged, water-oxidizing, and nucleolus-targeted Pt(IV) complex with a distinct anticancer mechanism. J. Am. Chem. Soc. 142, 7803–7812 (2020).
Wong, D. Y. Q., Lim, J. H. & Ang, W. H. Induction of targeted necrosis with HER2-targeted platinum(IV) anticancer prodrugs. Chem. Sci. 6, 3051–3056 (2015).
To, W. P., Liu, Y., Lau, T. C. & Che, C. M. A robust palladium(II)-porphyrin complex as catalyst for visible light induced oxidative C-H functionalization. Chem. Eur. J. 19, 5654–5664 (2013).
Yang, X. et al. Characterization of G‐quadruplex/hemin peroxidase: substrate specificity and inactivation kinetics. Chem. Eur. J. 17, 14475–14484 (2011).
Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23, 1124–1134 (2017).
Lytle, N. K., Barber, A. G. & Reya, T. Stem cell fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer 18, 669–680 (2018).
Li, X., Kwon, N., Guo, T., Liu, Z. & Yoon, J. Innovative strategies for hypoxic‐tumor photodynamic therapy. Angew. Chem. Int. Ed. 57, 11522–11531 (2018).
Stamati, I. et al. Novel photosensitisers derived from pyropheophorbide-a: uptake by cells and photodynamic efficiency in vitro. Photochem. Photobiol. Sci. 9, 1033–1041 (2010).
Mandl, J., Mészáros, T., Bánhegyi, G. & Csala, M. Minireview: endoplasmic reticulum stress: control in protein, lipid and signal homeostasis. Mol. Endocrinol. 27, 384–393 (2013).
Lu, J. & Holmgren, A. The thioredoxin antioxidant system. Free Radic. Biol. Med. 66, 75–87 (2014).
Clarke, H. J., Chambers, J. E., Liniker, E. & Marciniak, S. J. Endoplasmic reticulum stress in malignancy. Cancer Cell 25, 563–573 (2014).
Steinegger, A., Wolfbeis, O. S. & Borisov, S. M. Optical sensing and imaging of pH values: spectroscopies, materials and applications. Chem. Rev. 120, 12357–12489 (2020).
Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486–541 (2018).
Kepp, O., Galluzzi, L., Lipinski, M., Yuan, J. & Kroemer, G. Cell death assays for drug discovery. Nat. Rev. Drug Discov. 10, 221–237 (2011).
Li, J. et al. Ferroptosis: past, present and future. Cell Death Dis. 11, 88 (2020).
Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247–250 (2017).
Zilka, O. et al. On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Central Sci. 3, 232–243 (2017).
Wang, B. et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct. Target. Ther. 6, 94 (2021).
Johnstone, T. C., Suntharalingam, K. & Lippard, S. J. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery and Pt(IV) prodrugs. Chem. Rev. 116, 3436–3486 (2016).
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111 (2017).
Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013).
Tao, K., Fang, M., Alroy, J. & Sahagian, G. G. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 8, 228 (2008).
Ouzounova, M. et al. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. Nat. Commun. 8, 14979 (2017).
Hunter, K. W. Jr Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp. Mol. Pathol. 82, 12–24 (2007).
Dierge, E. et al. Peroxidation of n-3 and n-6 polyunsaturated fatty acids in the acidic tumor environment leads to ferroptosis-mediated anticancer effects. Cell Metab. 33, 1701–1715 (2021).
Farrer, N. J. et al. A potent trans‐diimine platinum anticancer complex photoactivated by visible light. Angew. Chem. Int. Ed. 49, 8905–8908 (2010).
Wang, Z. et al. Phorbiplatin, a highly potent Pt(IV) antitumor prodrug that can be controllably activated by red light. Chem 5, 3151–3165 (2019).
Vichai, V. & Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 1, 1112–1116 (2006).
